Ghadeer Dawwas, PhD, MSc, MBA, is an Assistant Professor of Medicine in the Division of Epidemiology, Department of Medicine, at Vanderbilt University Medical Center. She is a Faculty Scholar at the Vanderbilt Center for Health Services Research (CHSR), and a member of Vanderbilt Translational and Clinical Cardiovascular Research Center (VTRACC).
Dr. Dawwas is a pharmacoepidemiologist and her research program uses readily available healthcare data to provide stakeholders including patients, clinicians, payers, and policymakers with evidence on the risk/benefit tradeoffs of therapeutic alternatives to improve clinical decision-making. The major themes of her research center on the evaluation of anticoagulants, research methods, and the intersection of comparative effectiveness research and health policy. Her most notable contribution stems from the work that evaluated apixaban and rivaroxaban in patients with venous thromboembolism (VTE) that, among other evidence, led CVS Caremark to reverse its decision regarding the removal of apixaban from CVS preferred formulary list.